Status:
UNKNOWN
Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
Lead Sponsor:
Liqiang Zhong
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
(1) Evaluate the efficacy of apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer. Whether it can prolong Progression Free Survival (PFS), overall survival (OS...
Detailed Description
Standard second line chemotherapy includes chemotherapy based on irinotecan or chemotherapy based on oxaliplatin. Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively ...
Eligibility Criteria
Inclusion
- Male or female aged 18 to 70 years old;
- Histologically or cytologically proven patients with metastatic colorectal cancer have undergone a first-line standard regimen recommended by the NCCN guidelines for progression;
- According to the RECIST 1.1 criteria, the patient has at least one target lesion that can measure the diameter;
- ECOG PS ≤ 2;
- Expected survival time of more than 12 weeks.
- The level of organ function must meet the following requirements:
- Bone marrow: neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet ≥ 75 × 10\^9/L, hemoglobin ≥ 90g/L.
- Liver: serum bilirubin ≤ 2 times the upper limit of normal, aminotransferase AST and ALT ≤ 2.5 times the normal upper limit.
- Kidney: Serum creatinine ≤1.5 times upper limit of normal.
- Patient compliance is good;
- Understand and voluntarily sign a written informed consent.
Exclusion
- Other previous or concurrent malignancy, except cured skin basal cell carcinoma and cervical carcinoma in situ;
- Already known to be allergic to apatinib or any excipient;
- Use unapproved drugs or other test medications within 4 weeks prior to enrollment;
- There are many factors that affect oral medications (such as inability to swallow, chronic diarrhea and intestinal obstruction);
- Patients with a history of CNS metastases or CNS metastases;
- A history of bleeding, with any serious grading within 4 weeks prior to screening reaching a bleeding event of 3 degrees Celsius or greater in CTCAE4.0;
- Serious infection;
- Serious cardiovascular disease: uncontrolled hypertension, unstable angina, grade 3-4 heart failure (NYHA standard), congestive heart failure;
- urinary routine urinary protein ≥ ++ and confirmed 24-hour urinary protein quantitation\> 1.0 g;
- Within 30 days after major surgery;
- Thrombotic disease. Anemia or venous thrombosis occurred in the previous year, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, pulmonary embolism, etc.;
- Those with history of psychotropic substance abuse who can not be abstinent or have mental disorders;
- Have clinical symptoms, need clinical intervention pleural effusion or ascites;
- At the investigator's discretion, there is a serious concomitant condition that compromises the patient's safety or affects the patient in completing the study.
Key Trial Info
Start Date :
February 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03412994
Start Date
February 28 2018
End Date
February 28 2021
Last Update
January 29 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.